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Summary 
CD44 is a major cell surface receptor for the extracellular matrix glycosaminoglycan hyaluronan 
(HA). However, the ability of CD44 to bind ligand is strictly regulated. Three activation states 
of CD44 have been demonstrated:  (a) inactive;  (b) inducible (by certain CD44-specific mAb); 
and (c) constitutively active. Starting with two parental cell lines expressing CD44 in the inactive 
state, a pre-B cell (RAW 253) and a fibroblast (L cells), we used fluorescence-activated cell sorting 
with fluorescein-conjugated hyaluronan in the presence of inducing mAb to derive variant cell 
lines with CD44 in the inducible state.  Constitutively active derivatives were isolated from the 
inducible variants by a further round of fluorescence-activated cell sorting in the absence of in- 
ducing antibody. However, constitutively active variants could not be isolated directly from pa- 
rental cells expressing CD44 in the inactive state.  These results suggest that two genetic events 
must occur to obtain an active CD44-HA receptor from an inactive receptor. Variant and parental 
cell-derived CD44 molecules exhibited differences in migration on sodium dodecyl sulfate-poly- 
acrylamide gel electrophoresis that were partly attributable to differences in N-linked glycosyla- 
tion. Furthermore,  culture in tunicamycin for 2-3 d converted parental and inducible cell lines 
into cells showing constitutive CD44-mediated HA binding.  Also, removal of cell surface gly- 
co  saminoglycan chains by culture of cells inp-nitrophenyl ~-D-xylopyranoside or treatment with 
chondroitinase ABC resulted in conversion of cells with an inactive CD44 receptor to an induc- 
ible state.  These results indicate that carbohydrate side chains of CD44 and/or other molecules 
on the cell surface that interact with CD44 are potentially involved in regulating the HA-binding 
function  of CD44 on the cell surface. 
C 
D44 is a cell surface receptor  for hyaluronan  (HA), 1 
a  glycosaminoglycan  (GAG)  that  is  abundantly  dis- 
tributed in extracellular spaces (1-3). CD44 is found on di- 
verse cell types and is thought  to be involved in a number 
of functions, including lymphocyte activation, recirculation 
and homing, tumor metastasis, hematopoiesis, and HA me- 
tabolism (1, 3, 4). The HA receptor function of CD44 ap- 
pears to be strictly regulated,  with many cells that express 
CD44 failing to exhibit receptor function (1, 5). The mecha- 
nisms of this regulation  are unknown, but the importance 
of regulated receptor function may be reflected in the corre- 
lation of altered CD44 expression with malignancy, inflam- 
mation,  and  autoimmunity,  as well as cell activation  in  a 
normal  immunological  response (1,  4). 
:Abbreviations used in  this paper: fl-v-xyloside, p-nitrophenyl H-D- 
xylopyranoside; BZ~GalNAc, benzyl 2-acetamido-2-deoxy-ol-v-galactopy- 
ranoside; F1-HA, fluorescein-conjugated  HA; GAG, glycosaminoglycan; 
HA, hyaluronan. 
We have previously described three activation states of CD44 
with respect to HA-binding function (1, 6-8). Here we show 
that a single cell line can express CD44 in each of the three 
activation states as the result of a limited number of muta- 
tion events. By comparison of variant cell lines differing in 
CD44-mediated HA-binding function, we define differences 
in glycosylation that are potentially responsible for differences 
in CD44-mediated ligand binding. 
Materials  and Methods 
Cell Lines and Antibodies.  RAW 253 (a pre-B lymphoma,  9), 
L.TK- (K) strain of L cell fibroblasts (10), and the variant cell lines 
derived from them were cultured in DMEM with 10% horse serum. 
Tissue culture  supernatants  of the CD44-specific mAb IM7(11), 
IRAWB14 (7), and KM81 (12) were used for immunoprecipita- 
tion,  induction  of HA binding,  and inhibition  of HA binding, 
respectively. Fluorescein-conjugated IM7 (7) was used for quanti- 
tation  of cell surface CD44 by flow cytometry. 
Cell Sorting and Flow Cytometry.  Cell sorting to derive mutant 
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performed as previously described (13). Briefly, 2-3  x  107 cells 
were labeled with fluorescein-conjugated  HA (F1-HA) (14) in the 
presence or absence of inducing mAb IRAWB14. Rare positive 
events, with relative fluorescence greater than tenfold above the 
bulk of  the population, were isolated by fluorescence-activated  cell 
sorting on a FACStar+  |  (Becton Dickinson and Co., Cockeysville, 
MD). After three or four rounds of sorting, when a distinctly posi- 
tive population was evident, the cells were cloned, and positive 
clones were selected after analysis  by flow cytometry. Flow cyto- 
metric analysis was performed as previously described (15) on a 
FACScan  |  (Becton Dickinson and Co.) using FI-IM7 to measure 
CD44 expression, F1-HA to measure HA binding, and F1-HA plus 
IRAWB14 to measure inducible HA binding. 
Reverse Transcription  and PCR.  Total  RNA was isolated from 
both sets of parental and variant cell lines and from control cell 
lines transfected with higher relative molecular mass isoforms of 
CD44 (8) using an RNA isolation kit (Stratagene, La Jolla, CA). 
Reverse transcription, PCR amplification, and Southern blotting 
were as previously described (16). Primers used for PCR were up- 
stream and downstream  of  the site of  insertion of  alternatively  spliced 
exons (16). 
Iodination and ImmunoFrecipitation.  Iodination and immunopre- 
cipitation were as previously described (17), using IM7 mAb su- 
pernatant plus anti-rat Ig-coupled Sepharose (Pharmacia Biotech, 
Inc., Piscataway,  NJ). Treatment of  precipitates with N-glycosidase 
F (Boehringer Mannheim Corp., Indianapolis, IN) was performed 
as described by Camp et al. (18). 
Inhibition of Glycosylation.  Cells  were cultured in DMEM with 
10% horse serum for 2 or 3 d with the following inhibitors of 
glycosylation:  2 mM deoxymannojirimycin  (Calbiochem-Novabio- 
chem Corp., La Jolla, CA); 5/~g/ml tunicamycin (Calbiochem- 
Novabiochem Corp.);  1 mM p-nitrophenyl ~-D-xylopyranoside 
(~-D-xyloside; Sigma Chemical Co., St. Louis, MO); 2 mM benzyl 
2-acetamido-2-deoxy-c~-D-galactopyranoside  (BZccGalNAc;  Sigma 
Chemical Co.). Treated and control cells were analyzed for CD44 
expression and HA-binding function by flow cytometry. Aliquots 
of cells were also lysed in extraction buffer (10 mM Tris, 50 mM 
sodium acetate, 150 mM NaC1, 5 mM EDTA, pH 7.5) with 1% 
Triton X-100 and 1 mM PMSF, diluted in sample buffer, run on 
SDS-PAGE, and immunoblotted  (as  described in  19)  to detect 
changes in the relative molecular mass of CD44. 
Immunoblotting.  lmmunoblotting of cell lysates  was performed 
as previously  described (19) using IM7 mAb supernatant or an mAb 
specific for the transferrin receptor cytoplasmic  domain, H68.4 (20), 
and horseradish peroxidase-coupled rabbit anti-rat Ig (Boehringer 
Mannheim Corp.). Blots were visualized using the enhanced che- 
miluminescence detection system (Amersham Corp.,  Arlington 
Heights, IL). 
the HA-binding function of CD44. The derivation of these 
cell lines is outlined in Fig. 1, and the phenotype of the L 
cell series of  variants is shown in Fig. 2. By enrichment sorting 
of the parental cell lines for rare HA-binding cells using F1-HA 
plus the CD44-specific mAb ItLAWB14, stable lines that bind 
F1-HA in the presence  of IRAWB14 mAb, but which do 
not bind FI-HA in the absence of inducing antibody, were 
obtained. These cell lines are termed "inducible." (Figs. 1 and 
2, middle row). Enrichment sorting of inducible cell lines for 
cells able to bind FI-HA in the absence of IRAWB14 allowed 
isolation of cell lines with a constitutively active CD44 func- 
tion (Figs.  1 and 2,  bottom row). These latter cell lines are 
termed "active." Cell surface CD44 levels of parental and in- 
ducible cell lines were not significantly different. Active variant 
cell lines showed a two- to threefold increase in cell surface 
CD44 (Fig.  2, right column). Though the increase in CD44 
expression may contribute to the HA-binding activity of the 
constitutively "active" variant cell lines  (17), it is unlikely 
that this increase alone accounts for the change in phenotype 
from inducible to active, since we have shown previously that 
inducible cell lines selected for high levels of CD44 expres- 
sion retain their inducible phenotype (13). The L cell-derived 
variant lines and the inducible RAW 253 variant have been 
stable for >1 yr in culture. The active RAW 253 variant has 
been recloned several times to maintain the majority of cells 
in the active  state. 
We were not able to select a cell line with constitutively 
active CD44 function directly from an inactive parental line 
by sorting with F1-HA in the absence of inducing antibody. 
Previous studies have estimated that the enrichment sorting 
method allows isolation of variants that are present at a fre- 
quency of 10-6-10-s (21). This is the approximate frequency 
of a mutation event in a single copy of a single gene (22). 
Thus, if the basis of the phenotypic changes observed is due 
to mutation, then each variant probably represents  a single 
mutational event, with two mutations required to generate 
a constitutively active phenotype from the inactive parent, 
Isoform Expression and Cytoskeletal Association in  Variant 
Cells.  One possible mechanism for activating the function 
of CD44 in variant cells would be a change in splicing of 
CD44 exons leading to expression  of a novel CD44 isoform 
with an altered ability to bind HA. This possibility was ex- 
amined by reverse transcription and PCR amplification of 
CD44 RNA from parental and variant call lines. As shown 
Results 
Derivation of Cell Lines with Alterations in CD44 Function. 
Parental cell lines RAW 253 and L.TK-(K) strain L cells ex- 
press substantial levels of the standard 85-90-kD isoform of 
CD44, but they do not bind the CD44 tigand HA, even in 
the presence of the inducing CD44-specific mAb IRAWB14 
(see Figs. 2 and 5, top row). The activation state of these cells 
and of the CD44 molecules expressed on their surface is termed 
"inactive." Using fluorescence-activated  cell sorting, we de- 
rived stable variant lines that differ from the parent lines in 
CD44  HA  HA Bncllng 
Actlvmion State  ExpreJon  ~n~ng  § IRAWB14 
{INACTIVE (pMtn,) ]  ~,  --  -- 
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Figure 1.  Derivation  of variants in HA receptor function. Variant cell 
lines were  derived  from  "inactive"  parental  cell  lines  as described  in Materials 
and Methods. CD44 expression  and HA-binding  phenotype  were deter- 
mined by flow cytometry  (see Fig. 2). 
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lines. Cells were incubated  with F1-HA (left column), F1-HA in the pres- 
ence of inducing  mAb IRAWB14  (center  column), or fluorescein-conjugated 
IM7 specific  for CD44 (right  column) and analyzed  by flow  cytometry.  Rel- 
ative fluorescence  was normalized  such that unlabeled  cells (indicated  by 
the dotted insert in each panel) had a mean  relative  fluorescence  intensity 
of 1.0. 
in Fig. 3, all lines expressed  the standard isoform of CD44. 
No novel isoforms were detected in the variant cell lines (Fig. 
3, lanes a-f).  Control cell lines expressing higher relative mo- 
lecular mass isoforms of CD44 (8) had the expected larger 
reverse transcription-PCR products (Fig. 3, lanes g and h). 
In L cells, a portion of the cell surface CD44 is insoluble 
Figure 3.  CD44  isoform  expression in parental and variant cell lines. 
Reverse  transcription,  PCK amplification,  and Southern  blotting  were  per- 
formed as described in reference 16. Total RNA was isolated from cell 
lines as follows:  parental  L cells (lane  a); inducible  L cells (lane  b); consti- 
tutively  active  L cells (lane  c); parental  RAW 253 (lane  d); inducible  RAW 
253 (lane e); active RAW 253 (lane  f); and CD44-negative AKR1 cells 
transfected  with higher  relative  molecular  mass  CD44 isoforms,  described 
in reference 8, containing  variant exons  v8-vl0 (lane  g) and v9-vl0 (lane 
h). The legend indicates  bp, and the expected size of standard CD44H 
is 400 bp. 
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in Triton X-IO0  (19). The proportion of Triton X-100-in- 
soluble CD44 was not changed between parental L cells and 
variants for HA-binding function (data not shown). Also, 
RAW 253 cells and variants derived from them lack a Triton 
X-100-insoluble  CD44 component. These results indicate that 
Triton X-100 insolubility of CD44 or lack of Triton X-100 
insolubility does not correlate with HA-binding phenotype. 
Variant CD44  Molecules Show Differences in  Glycosylation. 
Slight differences  in apparent relative molecular mass were 
seen when iodinated and immunoprecipitated CD44 mole- 
cules from parent and variant cell lines were analyzed on SDS- 
PAGE. These differences were seen only when immunoprecipi- 
tates were run on long 10% acrylamide gels, and/or run for 
longer times (after the marker dye had reached the bottom 
of the gel). CD44 from constitutively active variants migrated 
more rapidly than CD44 from inducible variants, which in 
turn migrated more rapidly than CD44 from parental cells. 
This suggested that inactive CD44 was more heavily glycos- 
ylated than the inducible form and that inducible CD44 was 
more heavily glycosylated than the active form. This result 
was found for both L cells and RAW 253 and is shown for 
RAW 253  and its variants in Fig. 4  (A, lanes a-d,  and B, 
lanes a-c). Slight differences in migration were also seen when 
comparing migration of transferrin receptor from the three 
RAW 253-derived cell lines, indicating that these differences 
were not specific to CD44 but affected multiple glycopro- 
teins. The differences in apparent relative molecular mass of 
CD44 could be partly attributed to N-linked glycosylation: 
As shown in lanes e-h of Fig. 4 A, most of the differences 
in mobility were eliminated by treatment of the CD44 im- 
munoprecipitates with N-glycosidase F, though parental cell 
CD44 still migrated slightly more slowly than the two variant 
forms after N-glycosidase F treatment. When cells were io- 
dinated and CD44 was immunoprecipitated after culture in 
5 /~g/ml tunicamycin, the differences  in migration of the 
deglycosylated lower migrating bands of CD44 from the three 
cell lines were again largely eliminated, but the deglycosylated 
band of the parental cells still migrated above those of the 
two variants (Fig. 4 B, lanes d-f).  The lower relative molec- 
ular mass band in tunicamycin-treated cells always migrated 
faster than CD44 deglycosylated by treatment with N-glycosi- 
dase F,  suggesting either that N-glycosidase F  did not re- 
move all of the N-linked sugars, or that tunicamycin affected 
other posttranslational modifications of CD44 besides N-gly- 
cosylation. A fraction of the immunoprecipitated CD44 from 
tunicamycin-treated cells migrated similarly to CD44 of un- 
treated cells (Fig. 4 B, lanes d-f  upper bands). This observa- 
tion suggests that CD44 does not turn over completely during 
the period of tunicamycin treatment. 
Inhibition of  N-linked Glycosylation Alters the Activation State 
of CD44.  The HA-binding function of CD44 in tunica- 
mycin-treated cells (after 2 d in the drug) is shown for the 
RAW 253 series of cell lines in Fig. 5 (bold solid lines). After 
tunicamycin treatment, parental RAW 253 cells (Fig. 5, upper 
row), were completely inducible by IRAWB14 mAb (upper 
right panel),  and some cells bound F1-HA constitutively, i.e., 
without induction by IP-,AWB14 (upper left panel). Inducible 
RAW 253 variants cultured in tunicamycin-bound HA con- Parent 
RAW 253 
FI-HA alone 
. ,~~.......,  ........ ,  ........ ,  ......... 
FI-HA + IRAWB14 
Inducible 
RAW 253 
Figure 4.  Migration of CD44 from RAW 253 parent and variant cells 
on SDS-PAGE. Surface  iodinated cells  were solubilized  in 1% NP-40, and 
CD44 was immunoprecipitated. Samples were run on 10% acrylamide 
gels until ,x,60 min after the bromophenol blue marker dye ran off the 
bottom of the gel. (A) Lanes a-d are untreated CD44 immunoprecipi- 
tates. Lanes e-h are CD44 immunoprecipitates digested overnight with 
N-glycosidase F after denaturation in SDS and mercaptoethanol. Lanes 
a and e were from parental cells; lanes b andfwere from inducible cells; 
and lanes c, d, g, and h were from two clones of constitutively active  cells. 
(/3) Cells were cultured for 28 h in the absence (lanes a-c)  or presence 
(lanes d-f) of 5 #g/ml tunicamycin; parental cells (lanes  a and d); induc- 
ible cells (lanes b and e); and constitutively active cells (lanes c and f). 
Migration of molecular  mass standards  in kilodaltons  is indicated  on the left. 
stitutively (Fig.  5,  middle  left panel).  The constitutively ac- 
tive HA-binding  variant,  which  in  this  experiment bound 
HA only weakly in the absence of tunicamycin (Fig. 5, thin 
solid line,  lower left panel),  bound HA much more efficiently 
after culture in tunicamycin (Fig.  5,  bold solid line,  lower left 
panel).  Thus,  tunicamycin converted parental and inducible 
lines to the active state and enhanced the HA-binding func- 
tion of active cells. 2 d  (42-48 h) was required to effect the 
maximum change in HA-binding function shown in Fig. 5, 
and  longer  treatment  resulted  in  toxicity to the cells.  The 
same changes in HA-binding phenotype were obtained with 
the  L  cell  series  of lines,  except  that  culture  for  3  d  in 
tunicamycin was  tolerated and was  required to convert the 
cells to an active phenotype. HA binding of treated cells was 
mediated by CD44 as shown by inhibition of F1-HA binding 
with  the CD44-specific mAb  KM81  (data not  shown).  In 
other experiments, tunicamycin treatment converted the in- 
Active 
RAW 253 
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Figure 5.  Flow  cytometric  analysis  of  the HA-binding  function of RAW 
253 parental and variant cell  lines in the presence  and absence  of inhibitors 
of glycosylation.  Cells were cultured for 42 h in the presence  of no inhib- 
itor (thin  solid  line), 1 mM/3-D-xyloside  (dotted  line), or 5/xg/ml tunicamycin 
(bold solid line), and stained with R-HA alone (left column) or F1-HA in 
the presence  of the inducing  mAb IRAWB14  (tight  column). Relative  fluores- 
cence was normalized such that mean fluorescence  intensity of unstained 
cells was 1.0. 
ducible T  lymphoma SAKtLTLS12 (described in 4  and  13) 
to a constitutively active state (data not shown).  Treatment 
with tunicamycin either slightly reduced or did not signifi- 
cantly affect cell surface CD44 expression (data not shown). 
Tunicamycin inhibits N-linked glycosylation of glycopro- 
teins by preventing formation of the lipid-linked saccharide 
donor, which is transferred as a unit to the nascent polypep- 
tide (23).  Other  inhibitors,  such  as  deoxymannojirimycin, 
inhibit trimming of the mannose-rich immature carbohydrate 
structure linked to asparagine (23). When parental and variant 
cell lines were cultured for 3 d in 2 mM deoxymannojirimycin, 
the HA-binding phenotype of the cell lines did not change. 
Thus,  inhibition  of processing of N-linked  sugars  was  not 
suffident to alter the functional state of CD44. The only clear 
effect of deoxymannojirimycin treatment was that the active 
variant of RAW 253, which showed relatively weak consti- 
tutive HA binding, now bound F1-HA more efficiently, such 
that  all  cells  showed detectable binding  (data not  shown). 
In other experiments,  inhibition of O-linked glycosylation 
by culture for 3  d  in 2  mM BZotGalNAc (24)  also did not 
influence the function of CD44 in any of the cell lines (data 
not shown).  Western blotting  to detect CD44  from deoxo 
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there was a significant reduction in relative molecular mass 
as a result of these treatments. Inhibition of O-linked glycosy- 
lation reduced the difference in migration between parental 
cells and the two variants, possibly accounting for the com- 
ponent of the differential migration that was not eliminated 
by inhibition of N-linked glycosylation. Lectin-binding analysis 
confirmed that deoxymannojirimycin-treated  cells expressed 
mannose-rich cell surface carbohydrates and lacked more ter- 
minal sugar structures. Neuraminidase treatment of parental 
RAW 253 cells did not change the HA-binding properties 
of these inactive cells. The effectiveness of the enzyme treat- 
ment was monitored by binding of lectins sensitive to the 
presence of terminal sialic acid residues (data not shown). 
Culture of cells in 3-D-xyloside prevents the addition of 
chondroitin sulfate GAG side chains to proteoglycan core pro- 
teins (25). We examined the effect of culture in I mM xylo- 
side on CD44 function in RAW 253 cells (Fig. 5, dotted lines). 
Parental cells cultured in/~-D-xyloside acquired inducible HA- 
binding activity, but still did not bind HA constitutively (upper 
panels, right and left, respectively). Inducible variant cells were 
not detectably affected. Constitutive HA-binding cells bound 
F1-HA more efficiently after culture in 3-D-xyloside (lower 
left panel).  The same results were obtained with the L cell 
series of lines upon culture in 3-D-xyloside. Parallel cultures 
in the presence of the inactive isomer, ot-D-xyloside, showed 
no effect on HA binding. These results were confirmed by 
treatment of intact RAW 253 cells with chondroitinase ABC, 
which digests chondroitin sulfate side chains (as well as HA). 
Again, parental inactive cells were converted to the inducible 
state, but no other changes in phenotype were found. It should 
be noted that tunicamycin has also been shown to selectively 
inhibit proteoglycan synthesis in some cell types (26). Thus, 
the effect of tunicamycin on HA-binding phenotype could 
represent combined influences on proteoglycan and N-linked 
carbohydrate synthesis. Hyaluronidase treatment, on the other 
hand, had no effect on HA binding in either the presence 
or absence of IRAWB14-inducing mAb, indicating that failure 
to bind F1-HA was not due to endogenous synthesis of HA 
(data not shown). Western blotting of CD44 molecules from 
parental and variant RAW 253 cell lines did not show any 
detectable change in the migration in SDS-PAGE  of CD44 
from B-D-xyloside-treated cells compared with untreated cells, 
indicating that the bulk of CD44 molecules in these cells 
was not modified with chondroitin sulfate side chains. 
Maintenance of the Activation State of CD44 Does Not Re- 
quire Cell Metabolism.  To determine whether active cell me- 
tabolism was required to maintain the functional state of CD44 
in parental or variant cells, cells were fixed in 2% parafor- 
maldehyde in a periodate lysine buffer designed to maintain 
carbohydrate structure (27)  for 20 rain at 4~  washed in 
PBS, and held overnight at 4~  in PBS. After this treatment, 
cells were completely permeable to propidium iodide and 
trypan blue (15 and data not shown). When assayed for HA 
binding in the presence and absence  of inducing mAb, the 
cells retained the same HA-binding properties that were found 
in living cells: Parental cells were inactive, inducible cells bound 
HA only in the presence of IRAWB14 mAb, and active cells 
bound HA constitutively (data not shown). 
Discussion 
CeUular regulation of the ligand-binding function of adhe- 
sion receptors controls the timing and specificity of cell adhe- 
sion in cell-cell and cell-substrate interactions. CD44 shares 
this property of regulated function with many of the inte- 
grins and with selectins (28).  Though there is a great deal 
of heterogeneity in the CD44 family of cell surface mole- 
cules, due to alternative splicing and posttranslational modifi- 
cations (1), it is not yet clear how these variations in CD44 
molecular structure affect ligand-binding function. By com- 
paring lines with different ligand-binding properties derived 
from a common parent, we sought to elucidate factors in- 
volved in regulating receptor function. 
Here we have provided genetic evidence for three activa- 
tion states of CD44 with respect to HA receptor function. 
The requirements for selecting variant lines suggest that two 
genetic events separate inactive and active states in the two 
series of cell lines that we have characterized here (see Fig. 
1). However, the genes involved here are probably not the 
only ones that act to alter CD44 function. Any gene whose 
product influences CD44 function could give rise to a new 
activation state, and combinations of such gene products could 
give still more activation states. Additional assays might allow 
us to distinguish additional activation states. 
Studies by Hathcock et al. (29) as well as those presented 
here noted that cells able to bind HA had less heavily glycos- 
ylated CD44 molecules than cells that failed to bind HA. 
We have now shown that modification of the carbohydrate 
composition of the cell surface can have dramatic effects on 
CD44 function. The general finding from these studies is 
that removal of cell surface carbohydrate results in a CD44-HA 
receptor with ability to bind HA either inducibly or constitu- 
tively. The treatments used to affect carbohydrate structure 
act on glycoproteins or proteoglycans throughout the cell. 
Thus, though we could demonstrate changes in CD44 glycos- 
ylation upon treatment with tunicamycin, we do not know 
whether the observed changes in function are due to deglycosy- 
lation of CD44 and/or deglycosylation of some other mole- 
cule(s) on the cell surface that influence(s) CD44 function. 
In preliminary experiments using HA-conjugated Sepharose 
beads (30) to assay the binding function of detergent-solu- 
bilized CD44 from the RAW  253-derived cell lines,  only 
lysates from the constitutively active cells bound the beads. 
With lysates from tunicamycin-treated cells, the lower rela- 
tive molecular mass deglycosylated band of all three cell lines 
bound, suggesting that the HA-binding properties of the cells 
are a consequence of posttranslational modification of CD44 
itself. 
In the case of 3-D-xyloside and chondroitinase treatments, 
we could not detect any change in the mobility of CD44 
on SDS-PAGE, suggesting that removal of GAG chains from 
some other molecule may have affected CD44  function in 
inactive cells. One possibility is that an endogenous ligand 
435  Lesley  et al. for CD44 is expressed on the cell surface and blocks CD44 
function by occupying ligand-binding sites. Specific binding 
of CD44 to two chondroitin sulfate-containing proteoglycans 
has been described (31, 32). Another possibility is that a chon- 
droitin sulfate-containing molecule interacts with CD44 at 
some site distinct from the HA-binding region and alters CD44 
conformation or distribution. It is also possible that a minor 
component of cell surface CD44 contains chondroitin sul- 
fate side chains, or that chondroitin sulfate side chains are 
present on inactive CD44 but are too short to alter relative 
molecular mass detectably. 
The parental and variant cell lines we describe here show 
differences in  N-linked  glycosylation,  and  elimination  of 
N-glycosylation abolishes differences in CD44-HA receptor 
function. However, this does not prove that glycosylation 
differences are the basis of the differences in function in the 
variant cell lines. It is clear, however, that whatever the mech- 
anism responsible for the differences in HA-binding cell pheno- 
types, it does not require ongoing cell metabolism, as HA- 
binding phenotypes are maintained even in fixed cells (15 and 
this paper).  Thus,  HA-binding phenotype appears  to be a 
stable property of the cell surface environment that does not 
require active processes for its maintenance. 
We have shown previously that activation of HA binding 
by inducing mAb requires multivalent antibody and cross- 
linking of CD44  (15),  and that a mutant CD44 molecule 
expressed as a disulfide-bonded dimer on the cell surface binds 
HA more efficiently than wild-type CD44 (17). As a result 
of these studies, we have postulated that HA binding by CD44 
is promoted by close association of CD44 molecules in a mul- 
tivalent aggregate on the cell surface. This model has prece- 
dents in other experimental systems, as Dustin and Springer 
(28, 33)  have shown that aggregated CD2 and LFA-3 had 
10- and 200-fold higher avidity for substrate,  respectively, 
than monomeric forms. Mobility within the membrane has 
been shown to be a significant factor in contributing to adhe- 
sion between the CD2 and LFA-3, presumably by allowing 
clustering of receptors at a point of contact between cells (34), 
and carbohydrate side chains have been shown to restrict lateral 
diffusion of cell surface MHC class I molecules, as mutation 
of N-glycosylation sites  resulted in  increased mobility in 
fluorescence photo bleaching and recovery assays (35).  For- 
mation of muhivalent CD44 receptor might be prevented 
by restriction of mobility due to glycosylation and/or by charge 
repulsion of carbohydrate side chains terminating in charged 
residues (28).  Other possibilities  include more direct inhibi- 
tion of HA binding as a result of conformational or steric 
interference. 
Several treatments that inhibit glycosylation also enhanced 
HA binding of constitutively active RAW 253 variant cells 
(~-D-xyloside, deoxymannojirimycin, and tunicamycin), in- 
dicating that, even in the active state, receptor function was 
restricted by carbohydrate. A  recent study by Katoh et al. 
also found that HA binding by Chinese hamster ovary cells 
and several other cell lines was enhanced by deglycosylation 
(tunicamycin and neuraminidase treatment), again indicating 
restriction of receptor function by carbohydrate (see accom- 
panying article,  36).  In  our studies,  however, deoxyman- 
nojirimycin (or neuraminidase treatment of inactive RAW 
253  parental cells),  which eliminated most of the charged 
sugar residues from N-linked carbohydrate side chains, did 
not alter the function of CD44 in inactive and inducible cell 
lines. Therefore, the mechanism whereby N-linked glycosy- 
lation restricts CD44 function remains to be determined and 
may differ among different cell types. 
Bartolazzi et al. (37) have shown that, in one model system, 
the ability of CD44 to bind HA is required for the enhance- 
ment of metastatic behavior when CD44 is transfected into 
a nonmetastasizing cell line.  By selection of cells that vary 
in the HA-binding function of their cell surface CD44, we 
have shown that changes in the expression of only one or 
two genes are sufficient to convert a cell that does not bind 
HA to a constitutively active HA-binding phenotype. Muta- 
tions similar to those described here, which affect the regula- 
tion of CD44 ligand-binding function, might contribute to 
the function of CD44 in promoting tumor malignancy and 
metastasis. 
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